We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
Stephen Eck, M.D., Ph.D., has been promoted to vice president, head of medical oncology, and has more than 28 years of experience focused primarily in oncology research. Eck was most recently the vice president of translational medicine & pharmacogenomics at Eli Lilly.
Karen Reeves, M.D., is now vice president, global head of medical science, has more than 16 years of experience in phase 1 through 4 drug development in several therapeutic areas. She was a former vice president at Pfizer.
Mark Weinberg, M.D., MBA, has been promoted to therapeutic area head for CNS and pain and has more than 12 years of experience in the pharmaceutical industry, working across multiple therapeutic areas. He was most recently at Lundbeck where he focused on CNS.
Bernhardt Zeiher, M.D., is now vice president, therapeutic area leader of inflammation, immunology and infectious diseases, and has more than 13 years of experience in the pharmaceutical industry and most recently came from Pfizer.
